Non Small Cell Lung Cancer Clinical Trials in Omaha, Nebraska

15 studies are recruiting for non small cell lung cancer in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    University of Nebraska Medical Center Buffet Cancer Center, Omaha, Nebraska
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  2. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult par…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha, Nebraska
    Locations
    81 in total
    Run by
    AbbVie

    See if you can join NCT06568939 on ClinicalTrials.gov

  3. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Nebraska Medical Center (UNMC), Omaha, Nebraska
    Locations
    260 in total
    Run by
    Summit Therapeutics

    See if you can join NCT05899608 on ClinicalTrials.gov

  4. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

    Stage
    Phase 2
    Ages
    18 to 95
    Site
    Research Site, Omaha, Nebraska
    Locations
    97 in total
    Run by
    AstraZeneca

    See if you can join NCT05061550 on ClinicalTrials.gov

  5. Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Omaha, Nebraska
    Locations
    287 in total
    Run by
    AstraZeneca

    See if you can join NCT06357533 on ClinicalTrials.gov

  6. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    42 in total
    Run by
    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

  7. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist, Omaha, Nebraska
    Locations
    372 in total
    Run by
    Pfizer

    See if you can join NCT06758401 on ClinicalTrials.gov

  8. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Nebraska Medicine-Village Pointe, Omaha, Nebraska
    Locations
    75 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT06686771 on ClinicalTrials.gov

  9. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha, Nebraska
    Locations
    48 in total
    Run by
    AbbVie

    See if you can join NCT05005403 on ClinicalTrials.gov

  10. Repositioning Immunotherapy in VetArans With Lung Cancer

    This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska
    Locations
    7 in total
    Run by
    VA Office of Research and Development

    See if you can join NCT06275360 on ClinicalTrials.gov

  11. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    13 in total
    Run by
    Tasca Therapeutics

    See if you can join NCT07030257 on ClinicalTrials.gov

  12. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    58 in total
    Run by
    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

  13. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Omaha, Nebraska
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  14. Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

    The goal of this clinical trial is to: 1) evaluate the safety and recommended dose of the drug OT-101/Trabedersen when combined with Pembrolizumab and 2) determine the efficacy of the combination therapy in adults with certain types of Non-Small Cell Lung Cancer. The main question(s) it aims to ans…

    Stage
    Phase 1
    Ages
    19 and older
    Site
    University of Nebraska Medical Center, Omaha, Nebraska
    Run by
    University of Nebraska

    See if you can join NCT06579196 on ClinicalTrials.gov

  15. A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

    This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    7 in total
    Run by
    Avistone Biotechnology Co., Ltd.

    See if you can join NCT06046495 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.